DRUG
LH Suppression
Stimulation protocols
Progestin Priming Ovarian Stimulation (PPOS) Compared With Antagonist Protocol for Freeze-all Cycles
Status
Terminated
Phase
Not applicable
Enrollment
56
Locations
3
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
Stimulation protocols for IVF underwent several cycles of upgrading aiming to achieve reasonable outcomes with low-cost cycles. Antagonist protocols have been introduced as effective and comparable to long agonist regarding the outcomes. However, these protocols are still costly. Alternative protocols using progestin suppressions appear options for consideration.
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
Aug 12, 2019
Study start
Sep 10, 2019
Primary completion
Apr 30, 2020
Study completion
Apr 30, 2020
Results posted
Not reported
Registry updated
Jun 15, 2022
Outcomes
What the study measures.
Primary outcomes
Live Birth after first Vitrified-warmed cycle
Time frame · 42 weeks of gestation
Delivery of one or more viable infants \> 20th weeks of gestation
Secondary outcomes
Biochemical pregnancy
Time frame · 14 days after egg retrieval
positive human chorionic Gonadotrophin (βhCG) ≥ 10 IU/L
Clinical pregnancy
Time frame · within 12 weeks of gestation
registered sacs with a heartbeat on ultrasound at 7th weeks of gestation
Ongoing pregnancy
Time frame · within 24 weeks of pregnancy
continued viable pregnancy \> 20th weeks of gestation
Miscarriage
Time frame · Within 20 weeks of pregnancy
loss of pregnancy ≤ 20th weeks of gestation
Term live-birth for vitrified-warmed transfer
Time frame · Within 42 weeks of gestation
Delivery of one or more viable infants ≥37 weeks of gestation
Preterm Birth
Time frame · Within 42 weeks of gestation
delivery of one or more viable infants \< 37th weeks of gestation
Very preterm birth
Time frame · Within 42 weeks of gestation
delivery of one or more viable infants \< 32nd weeks of gestation
Low birth weight babies
Time frame · Within 24 hours of delivery
Babies with \< 2500 gm
Congenital malformation
Time frame · Within one month of delivery
delivery of congenitally malformed babies
Still birth
Time frame · Within 42 weeks of gestation
delivery of nonviable babies \> 20 weeks of gestation
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 40 Years
- Sex
- FEMALE
- Healthy volunteers
- No
Inclusion Criteria: 1. Women age of ≥ 18 to ≤ 40; 2. BMI of ≤ 31; 3. All indication for freeze-all 4. PCOS; 5. Women who have ≥ 1 year of primary or secondary infertility; 6. Tubal factor (unilateral, bilateral obstruction or salpingectomy); 7. Fresh ejaculate sperm of any count provided they have ≥ 1% normal forms and a motile fraction; 8. Women undergoing their first ICSI cycle or following a previous successful attempt; 9. Women undergoing only frozen-thawed embryo transfer; 10. Women with \> 8 mm endometrial thickness at the day of progesterone supplementation in the transfer cycle; 11. Women with no detected uterine abnormality on transvaginal ultrasound (e.g. submucosal myomas, polyps or septa). Exclusion Criteria: 1. Unilateral oophorectomy; 2. Uterine pathology or abnormality; 3. Abnormal karyotyping for them or their male partners; 4. History of repeated abortions or implantation failure; 5. Uncontrolled diabetes; 6. Liver or renal disease; 7. History of malignancy or borderline pathology; 8. Endometriosis; 9. Plan for PGD-A; 10. Severe male factor includes surgical sperm retrieval or cryopreserved sperm.
Study locations
3 registered sites.
Egypt. Showing up to 24 locations stored in the fast local snapshot.
Banon Fertility Center
Asyut, Egypt
IbnSina IVF Center, IbnSina Hospital
Sohag, Egypt
AlRahma Hospital
Sohag, Egypt
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Cetrorelix.
NCT IDStudyPhase / statusEnrollmentUpdated
Drospirenone-Primed Ovarian Stimulation Versus GnRH Antagonist Protocol in Poor Ovarian Responders Undergoing Freeze-All IVF/ICSI
Ahmed Saad · Poor Ovarian Reserve · Infertility (IVF Patients)
Phase 1 / Phase 2
Not yet recruiting
100
2026-07
Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist for Ovarian Stimulation in IVF/ICSI
Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita) · Infertility, Female · Ovulation Induction
Early Phase 1
Not yet recruiting
189
2026-07
A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Infertility
Phase 3
Recruiting
266
2026-07
Serum FSH Monitoring for Identification of an Optimal Range During Ovarian Stimulation
ART Fertility Clinics LLC · Ovarian Stimulation
Not applicable
Recruiting
150
2026-06
Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation
Bedaya Hospital · Infertility
Phase 2
Recruiting
120
2026-05
Progesterone Primed Protocol Versus GnRH Antagonist in With PCO Undergoing ICSI
Beni-Suef University · IVF · PCO
Phase 2 / Phase 3
Completed
200
2026-04
NATural Ovarian Stimulation
Assistance Publique - Hôpitaux de Paris · Infertility
Phase 4
Completed
129
2026-04
Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer
Institut Cancerologie de l'Ouest · Breast Cancer
Phase 2
Active, not recruiting
102
2026-03
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.